webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Maytansine

  CAS No.: 35846-53-8   Cat No.: BADC-00346   Purity: ≥95% HNMR HPLC MS 4.5  

Maitansine, a cytotoxic agent, inhibits the assembly of microtubules by binding to tubulin at the rhizoxin binding site.

Maytansine

Structure of 35846-53-8

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin
Molecular Formula
C34H46ClN3O10
Molecular Weight
692.2
Shipping
-20°C (International: -20°C)

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
5 mg $629 In stock
25 mg $1574 In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
NSC153858; NSC-153858; NSC 153858; (14S,16S,32S,33S,2R,4S,10E,12E,14R)-86-chloro-14-hydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-12,6-dioxo-7-aza-1(6,4)-oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl N-acetyl-N-methyl-L-alaninate;
IUPAC Name
[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[acetyl(methyl)amino]propanoate
Canonical SMILES
C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)C)C)\C)OC)(NC(=O)O2)O
InChI
InChI=1S/C34H46ClN3O10/c1-18-11-10-12-26(45-9)34(43)17-25(46-32(42)36-34)19(2)30-33(5,48-30)27(47-31(41)20(3)37(6)21(4)39)16-28(40)38(7)23-14-22(13-18)15-24(44-8)29(23)35/h10-12,14-15,19-20,25-27,30,43H,13,16-17H2,1-9H3,(H,36,42)/b12-10+,18-11+/t19-,20+,25+,26-,27+,30+,33+,34+/m1/s1
InChIKey
WKPWGQKGSOKKOO-RSFHAFMBSA-N
Melting Point
>165°C (dec.)
Appearance
Soild powder
Quantity
Milligrams-Grams
Shipping
-20°C (International: -20°C)
In Vitro
At the low concentrations of 0.5 to 2 microM, maytansine inhibited Tau-catalyzed tubulin assembly more effectively than it did MAP2-catalyzed assembly. This effect differed markedly from that of vinblastine, although both drugs bind competitively to tubulin. At the same low concentrations, vinblastine almost completely inhibited Tau- and MAP2-mediated tubulin assembly. At higher concentrations of 10 to 40 microM, a more striking difference was observed between the actions of the two drugs. Maytansine very effectively inhibited tubulin assembly promoted by either Tau or MAP2. Vinblastine also had this effect on MAP2-mediated tubulin assembly but in the presence of Tau induced extensive tubulin aggregation into spirals. In addition maytansine strongly inhibited vinblastine-induced Tau-dependent tubulin aggregation into spiral polymers. Even at very low concentrations, maytansine completely inhibited the effect of very high concentrations of vinblastine.
In Vivo
Maytansine, a potent clinically evaluated plant-derived anti-tumor drug, and its microbial counterpart, ansamitocin P-3, showed a substantially higher cytoxicity than many other anti-tumor drugs. The in vitro metabolism of maytansine and ansamitocin P-3 was studied after incubation with rat and human liver microsomes in the presence of NADPH, and with rat and human plasma and whole blood, using liquid chromatography/multi-stage mass spectrometry. There were no differences in maytansine metabolism between rat and human liver microsomes; however, the rate of metabolism of ansamitocin P-3 was different in rat and human liver microsomes. About 20% of ansamitocin P-3 was converted to its metabolites in rat liver microsomes and about 70% in human liver microsomes under the same conditions. Additionally, 10-O-demethylated ansamitocin P-3 was also detected in the urine after i.v. bolus administration of ansamitocin P-3 to Sprague-Dawley male rats. No metabolites were detected following incubation of maytansine and ansamitocin P-3 with human and rat whole blood and plasma.
NCT NumberCondition Or DiseasePhaseStart DateSponsorStatus
NCT01472887Diffuse Large B-cell LymphomaPhase 22018-01-25SanofiCompleted
NCT02221505cKIT-positive Solid TumorsPhase 12016-04-05Novartis PharmaceuticalsTerminated
NCT04596150NeoplasmsPhase 22021-10-28CytomX TherapeuticsRecruiting
NCT02947152Epithelial Ovarian CancerPhase 12020-12-08Novartis PharmaceuticalsTerminated
NCT01440179Acute Lymphocytic LeukaemiaPhase 22014-08-27SanofiTerminated (The study is stopped due to very modest activity compared to competitors)
1.Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma.
Nguyen M1, Miyakawa S1, Kato J1, Mori T2, Arai T2, Armanini M1, Gelmon K3, Yerushalmi R3, Leung S3, Gao D3, Landes G1, Haak-Frendscho M1, Elias K1, Simmons AD4. Clin Cancer Res. 2015 Dec 15;21(24):5552-62. doi: 10.1158/1078-0432.CCR-15-0468. Epub 2015 Aug 3.
PURPOSE: The RET proto-oncogene has been implicated in breast cancer, and the studies herein describe the preclinical and safety assessment of an anti-RET antibody-drug conjugate (ADC) being developed for the treatment of breast cancer.
2.Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment.
Askoxylakis V1, Ferraro GB1, Kodack DP1, Badeaux M1, Shankaraiah RC1, Seano G1, Kloepper J1, Vardam T1, Martin JD1, Naxerova K1, Bezwada D1, Qi X1, Selig MK1, Brachtel E1, Duda DG1, Huang P1, Fukumura D1, Engelman JA1, Jain RK2. J Natl Cancer Inst. 2015 Nov 7;108(2). pii: djv313. doi: 10.1093/jnci/djv313. Print 2016 Feb.
BACKGROUND: Central nervous system (CNS) metastases represent a major problem in the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer because of the disappointing efficacy of HER2-targeted therapies against brain lesions. The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has shown efficacy in trastuzumab-resistant systemic breast cancer. Here, we tested the hypothesis that T-DM1 could overcome trastuzumab resistance in murine models of brain metastases.
3.Taxanes-induced cutaneous eruption: another histopathologic mimicker of malignancy.
Prieto-Torres L1, Llamas-Velasco M2, Machan S3, Haro R3, de Asis S4, Carmo M5, Loredo A6, Del Puerto C7, Fried I8, Kempf W9, Cerroni L8, Requena L3. J Eur Acad Dermatol Venereol. 2016 Apr;30(4):638-44. doi: 10.1111/jdv.13475. Epub 2015 Nov 11.
BACKGROUND: Paclitaxel and docetaxel are antineoplastic drugs that bind the microtubules, producing the arrest of mitoses, which may be seen histopathologically. These histopathologic changes may simulate an intraepidermal keratinocytic malignant neoplasm, and an accurate diagnosis may be only established by clinicopathological correlation.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload Chemical Payload Protein Toxin Nanocarrier Microtubule Inhibitors DNA Damaging Agents RNA Polymerase Inhibitors Protein Degraders

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research ADC Payloads Explained: Current Types and Cutting-Edge Research Progress Tubulin Inhibitors - Highly Potential ADC Payloads

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Maytansine
Send Inquiry
Verification code
Inquiry Basket